Log Out

Puma Biotechnology (NASDAQ:PBYI) Shares Cross Above 200 Day Moving Average of $3.27

Financial News Live · Jan 14, 2023 10:41

Puma Biotechnology, Inc. (NASDAQ:PBYI – Get Rating) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $3.27 and traded as high as $4.80. Puma Biotechnology shares last traded at $4.69, with a volume of 425,658 shares trading hands.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on Puma Biotechnology in a research note on Wednesday, October 12th. They issued a "buy" rating for the company.

Get Puma Biotechnology alerts:

Puma Biotechnology Stock Performance

The company has a debt-to-equity ratio of 4.42, a current ratio of 2.04 and a quick ratio of 1.95. The stock has a 50 day simple moving average of $4.28 and a two-hundred day simple moving average of $3.28. The company has a market cap of $219.98 million, a PE ratio of 21.91, a PEG ratio of 2.06 and a beta of 0.92.

Puma Biotechnology (NASDAQ:PBYI – Get Rating) last issued its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.10. Puma Biotechnology had a return on equity of 84.14% and a net margin of 4.50%. The company had revenue of $57.10 million during the quarter, compared to analysts' expectations of $51.40 million. Equities analysts predict that Puma Biotechnology, Inc. will post 0.19 EPS for the current year.

Insider Transactions at Puma Biotechnology

In other news, CFO Maximo F. Nougues sold 10,499 shares of the company's stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $4.18, for a total transaction of $43,885.82. Following the completion of the sale, the chief financial officer now owns 100,427 shares in the company, valued at $419,784.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Alan H. Auerbach sold 27,241 shares of the company's stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $4.18, for a total transaction of $113,867.38. Following the completion of the sale, the chief executive officer now owns 6,852,638 shares in the company, valued at $28,644,026.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Maximo F. Nougues sold 10,499 shares of the company's stock in a transaction on Tuesday, January 3rd. The stock was sold at an average price of $4.18, for a total value of $43,885.82. Following the transaction, the chief financial officer now directly owns 100,427 shares in the company, valued at approximately $419,784.86. The disclosure for this sale can be found here. Insiders sold 43,034 shares of company stock worth $176,343 over the last 90 days. 21.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of PBYI. Panagora Asset Management Inc. grew its holdings in Puma Biotechnology by 3.6% during the first quarter. Panagora Asset Management Inc. now owns 205,138 shares of the biopharmaceutical company's stock worth $591,000 after acquiring an additional 7,066 shares during the period. BlackRock Inc. grew its holdings in Puma Biotechnology by 5.5% during the first quarter. BlackRock Inc. now owns 3,379,684 shares of the biopharmaceutical company's stock worth $9,733,000 after acquiring an additional 175,447 shares during the period. Mackenzie Financial Corp acquired a new position in Puma Biotechnology during the first quarter worth $35,000. Federated Hermes Inc. grew its holdings in Puma Biotechnology by 10.9% during the first quarter. Federated Hermes Inc. now owns 340,459 shares of the biopharmaceutical company's stock worth $981,000 after acquiring an additional 33,342 shares during the period. Finally, Prudential Financial Inc. grew its holdings in Puma Biotechnology by 4.8% during the first quarter. Prudential Financial Inc. now owns 186,936 shares of the biopharmaceutical company's stock worth $539,000 after acquiring an additional 8,500 shares during the period. Institutional investors and hedge funds own 60.58% of the company's stock.

Puma Biotechnology Company Profile

(Get Rating)

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors.